An Updated Economic Assessment of Moxidectin Treatment Strategies for Onchocerciasis Elimination.
Hugo C TurnerKlodeta KuraBarbara RothAnnette C KueselSally KinradeMaría-Gloria BasáñezPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024)
Moxidectin-based strategies could accelerate progress toward EoT and reduce programmatic delivery costs compared with ivermectin-based strategies. The costs of moxidectin to national programs are needed to quantify whether delivery cost reductions will translate into overall program cost reduction.